Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 1977

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology
  • Disease
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1977

License Grant
The Company entered into an exclusive sublicense agreement to manufacture and market DENSPM for all cancer indications; thermogenhylnorspermine (DENSPM), is in a Phase II clinical trial for the treatment of various solid tumor cancers – clinical trial.

IPSCIO Record ID: 3547

License Grant
The Licensor sublicensed the right to manufacture, market and distribute Clofarabine in the U.S. and Canada with respect to human cancer applications.
License Property
In 2004, Clofarabine was in pivotal Phase II Clinical Trials for the treatment of pediatric acute leukemias.  Clofarabine is also in Clinical Trials in a range of hematological cancers solid tumors.
Field of Use
Clofarabine is a purine nucleoside analogue, or a small molecule, which, is believed to be effective in the treatment of leukemia. Clofarabine may also be an effective agent to treat patients with solid tumor cancers.

IPSCIO Record ID: 2512

License Grant
This agreement grants the Company an exclusive world-wide license to patents, patent applications, and other intellectual property related to GCS-100 Material.
License Property
The Company's lead drug candidate GCS-100 (formerly known as GBC-590), a potential treatment for multiple forms of cancer, recently completed Phase II(a) clinical trials for pancreatic cancer and completed Phase II(a) clinical trials for colorectal cancer in 2001.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 359135

License Grant
Licensor entered into a license agreement with Chinese Licensee, thereby granting to Licensee exclusive rights to commercialize Licensor's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
License Property
Pritumumab, a drug candidate using monoclonal antibodies for the treatment of various cancer types. Pritumumab may offer an advantage over existing treatments. Pritumumab works by binding to a target on the surface of cancer cells called ectodomain vimentin (also referred to as cell-surface vimentin). The target, generally referred to as an antigen, is prevalent in many different tumor types and is not being targeted by any other biopharmaceutical companies. By binding to this target, Pritumumab is able to make the tumor cells “known” to the body’s immune system, resulting in potentially several types of immune responses, including anti-idiotype, apoptosis, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, leading to death of the cancer cells and overall depletion of the tumor.
Field of Use
Field of use is for the treatment of brain cancer and pancreatic cancer and exploring in its use against viruses.

IPSCIO Record ID: 25940

License Grant
An Australian Company signed a License for the clinical development, marketing and distribution of BrachySil in China. Under the terms of the License, we will manufacture BrachySil and Licensee will be responsible for clinical development, securing regulatory approval, marketing and distribution in China and Hong Kong. We will retain manufacturing rights for BrachySil under the License.
License Property
BrachySil, the company's lead BioSilicon application, is a targeted oncology product, which is presently in Phase II clinical trials for the treatment of both primary liver cancer and pancreatic cancer.

The technology company is about half way through U.S. regulatory testing of its modified silicon product BioSilicon that allows tiny pieces of radioactive material to be directly injected into primary liver tumours, as opposed to traditional radiotherapy that involves hitting a broader area with radiation.

Field of Use
“Licensed Field” 32P BioSilicon microparticles for use as a radiotherapy agent for the treatment or monitoring of solid cancerous tumours, including the primary tumour and metastases, which can be applied

i) interstitially within a cancerous tumour;

ii) into a resection cavity after surgical removal of a cancerous tumour;

iii) into the peritoneal cavity; or

iv) via the vasculature ( to the extent it becomes technically feasible).

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 5644

License Grant
Licensor grants to Licensee an exclusive worldwide license in the Field of Use to utilize the Subject Technology, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, during the term of this Agreement, unless sooner terminated as hereinafter provided. The agreement provides us with an exclusive worldwide royalty bearing license, including the right to grant sublicenses, to the intellectual property rights and know-how relating to PT-523 and all of its uses.
License Property
Patents related to this technology and covered by the license include  (i) a composition of matter patent, (ii) a utility application, and (iii) provisional use patents for multiple indications. The technology licensed to us includes one United States patent issued in 1988 and one pending patent application filed in April 2003.  PT-523, our lead product candidate, is an antifolate, cytotoxic agent (i.e., substance harmful to the structure and function of cells) designed for the treatment of solid tumors and hematological cancers. PT-523 is currently in Phase I clinical trials being conducted at the Dana-Farber Cancer Institute, Massachusetts General Hospital and Beth-Israel Deaconess Hospital.  This study commenced in April 2004 and is expected to involve 25-40 patients with seven already having received doses of PT-523.

Patent Rights means (1) United States Patent No. 4,767,761 (DFCI #111) entitled Ornithine Derivatives and their Use as Methotrexate Resistant Cell Inhibitors
60/376,615, (DFCI #774) entitled Pharmaceutically Active Ornithine Derivatives, Ammonium Salts Thereof and Methods of Making Same.

Field of Use
Field of Use means all commercial and non-commercial uses.

IPSCIO Record ID: 28677

License Grant
The Licensee entered into an Agreement in which the Licensor granted a worldwide License for the development, manufacture and commercialization of neratinib (oral), neratinib (intravenous) and PB357, and certain related compounds.

The License is exclusive with respect to certain patent rights owned by or Licensed to the Licensor.

License Property
From the closing date of the Agreement through December 31, 2011, the Licensor continued to conduct the existing clinical trials. The Licensor has agreed to continue to perform certain services in support of the existing clinical trials, at the Licensee expense for the first quarter of 2012.
Field of Use
The Licensee is obligated to commence a new clinical trial for a product containing one of these compounds within a specified period of time and to use commercially reasonable efforts to complete clinical trials and to achieve certain milestones as provided in a development plan.

Neratinib is a tyrosine kinase inhibitor under investigation for the treatment breast cancer and other solid tumors.

IPSCIO Record ID: 299281

License Grant
University grants a worldwide, exclusive license under the Patent Rights to make and have made, to use and have used, and to offer to sell, sell or import, and have offered to sell, sold or imported, the Licensed Products in the Field of Use, and to practice and have practiced the Licensed Processes and Know-How.

University also grants the right to enter into sublicensing agreements under the Patent Rights.

License Property
The University rights are for the Method for Synthesizing Epothilones and Epothilone Analogs and any other U.S. application owned by the University that has Valid Claims covering the manufacture, use, or sale of [trans-9,10-dehydro-epothilon,D].

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.

KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.

Field of Use
The Licensee is developing its epothilone, KOS-1584, in Phase 1 clinical trials and it has shown activity in patients with non-small cell lung, ovarian, breast, pancreatic, prostate and other cancers.

IPSCIO Record ID: 26866

License Grant
The Company acquired from Licensor, an individual, the exclusive rights to two issued United States patents and one patent application pending in the United States covering (i) the use of adenosine 5-diphosphate (ADP) and adenosine 5-triphosphate (ATP) to arrest and kill tumor cells (United States patent issued November 1989); (ii) the arrest of growth of tumor cells due to an increase in blood and plasma levels of ATP in a host resulting from the administration to the host of adenosine monophosphate (AMP) or ATP and a reduction in weight loss caused by cancer cachexia by administration of AMP or ATP (United States patent issued September 1991); and (iii) the utilization of adenosine nucleotides and/or adenosine and inorganic phosphates for elevation of liver, blood and blood plasma ATP concentrations (United States patent pending).
License Property
ATP – a sterile formulation of adenosine triphosphate – under development for the treatment of solid tumors or cancer-related cachexia.
Field of Use
The product has completed one single-center Phase I and one multicenter Phase II clinical trial, and the Company believes the results support the continued investigation of the drug as an adjunctive therapy that may improve the quality of life in patients suffering from non-small cell lung cancer.

IPSCIO Record ID: 27942

License Grant
The Company announced that it had begun to develop its lung cancer-specific drug compound L-DOS47.

For this purpose, the Company entered into a worldwide exclusive license with the Licensor, through which it obtained the right to combine an antibody that specifically binds to lung adenocarcinoma cells with minimal cross reactivity to other tissues with Company's DOS47â„¢ technology.

License Property
A patent application in respect of the antibody has been filed in Canada, the United States, and as a PCT filing. L-DOS47 is still in the pre-clinical stage though the Company intends to seek approval from the FDA for a Phase I clinical study in lung adenocarcinoma patients.
Field of Use
The rights granted relate to biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the treatment and prevention of cancer based on its proprietary technologies.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.